Rapid Response Fluorescence Probe Enabled In Vivo Diagnosis and Assessing Treatment Response of Hypochlorous Acid-Mediated Rheumatoid Arthritis

被引:141
|
作者
Feng, Huan [1 ]
Zhang, Zhiqiang [1 ]
Meng, Qingtao [1 ]
Jia, Hongmin [1 ]
Wang, Yue [1 ]
Zhang, Run [2 ]
机构
[1] Univ Sci & Technol Liaoning, Sch Chem Engn, Anshan 114051, Liaoning, Peoples R China
[2] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia
来源
ADVANCED SCIENCE | 2018年 / 5卷 / 08期
基金
中国国家自然科学基金; 澳大利亚研究理事会; 英国医学研究理事会;
关键词
fluorescence probes; hypochlorous acid; inflammatory diseases; rheumatoid arthritis; treatment response; LIVING CELLS; REACTIVE OXYGEN; LIVE CELLS; QUANTITATIVE APPLICATION; INFLAMMATORY RESPONSE; LUMINESCENT PROBES; DESIGN STRATEGIES; OXIDATIVE STRESS; FLOW-CYTOMETRY; CANCER-CELLS;
D O I
10.1002/advs.201800397
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Diagnosis and early assessment of the treatment response of rheumatoid arthritis (RA) necessitates a reliable bioanalytical method for rapid, sensitive, and specific detection of the hypochlorous acid (HOCl) biomarker in inflammatory diseases. Herein, two fluorescence probes, Probe-1 and Probe-2 are developed for quantitative monitoring and visualization of inflammatory response-related HOCl levels in vitro and in vivo. In the presence of HOCl, fluorescence OFF-ON response is obtained for both the probes as a result of specific HOCl-triggered CN bond cleavage reaction. Probe-1 and Probe-2 feature rapid response (<4 s), a high degree of sensitivity and selectivity toward HOCl, which allow them to be used for quantification of HOCl in a simulated physiological condition. Using Probe-2 as the probe, fluorescence imaging and flow cytometry analysis of HOCl levels in lysosome of inflammatory mimic cells, visualization of HOCl generation in endotoxin-induced inflammation of adult zebrafish and RA of mice are possible. Probe-2 exhibits high effectiveness for early assessment of the treatment response of HOCl-mediated RA in mice with an antiarthritic drug, methotrexate (MTX). The results demonstrate that Probe-2 is a powerful tool for future studies on diagnosis and monitoring treatment efficiency in a broad range of inflammatory diseases, including RA.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Utility of patient-reported outcomes in assessing treatment response in rheumatoid arthritis:: Humira® efficacy response optimization (HERO) trial.
    Wolfe, F.
    Michaud, K.
    Pincus, T.
    Kent, J. D.
    Pangan, A. L.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S424 - S425
  • [22] Response to Melatonin Can Mediate Its Vascular Protective Effect by Modulating Free Iron Level by Inhibiting Hypochlorous Acid-Mediated Hemoprotein Heme Destruction
    Rezzani, Rita
    Porteri, Enzo
    De Ciuceis, Carolina
    Bonomini, Francesca
    Rodella, Luigi F.
    Boari, Gianluca E. M.
    Rosei, Enrico Agabiti
    Rizzoni, Damiano
    HYPERTENSION, 2011, 57 (05) : E23 - E23
  • [23] Fatty acid-mediated endoplasmic reticulum stress in the liver in vivo: Differential response to saturated and unsaturated fatty acids.
    Nivala, Angela
    Reese, Lauren
    Hemenway, Erica
    Gentile, Christopher
    Pagliassotti, Michael
    FASEB JOURNAL, 2012, 26
  • [24] Patients with Rheumatoid Arthritis Achieve a Rapid Response When Treated with Certolizumab Pegol Irrespective of Background Treatment
    Cividino, Alf
    Fleischmann, Roy
    Keystone, Edward
    Luijtens, Kristel
    Furst, Daniel E.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2568 - 2568
  • [25] A rapid response near-infrared ratiometric fluorescent probe for the real-time tracking of peroxynitrite for pathological diagnosis and therapeutic assessment in a rheumatoid arthritis model
    Lu, Jiao
    Li, Zan
    Zheng, Xinrui
    Tan, Jiangkun
    Ji, Zhongyin
    Sun, Zhiwei
    You, Jinmao
    JOURNAL OF MATERIALS CHEMISTRY B, 2020, 8 (40) : 9343 - 9350
  • [26] Patients with rheumatoid arthritis achieve a rapid response when treated with certolizumab pegol irrespective of background treatment
    Fleischmann, Roy M.
    Keystone, Edward C.
    Luijtens, Kristel
    Furst, Daniel E.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S528 - S528
  • [27] An MMP-2 Responsive Nanotheranostic Probe Enabled Synergistic Therapy of Rheumatoid Arthritis and MR/CT Assessment of Therapeutic Response In Situ
    Chen, Xuan
    Dai, Deshen
    Ma, Junping
    Yu, Zipei
    Zhao, Junkai
    Yi, Changqing
    ADVANCED HEALTHCARE MATERIALS, 2023, 12 (26)
  • [28] Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: Focus on etanercept, a new biologic response modifier
    Fleischmann, RM
    CLINICAL THERAPEUTICS, 1999, 21 (09) : 1429 - 1442
  • [29] Response to: 'Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis' by Cutolo et al
    Aungier, Susan
    Cartwright, Alison J.
    Schwenzer, Anja
    Marshall, Jennifer
    Dyson, Mike R.
    Slavny, Peter
    Parthiban, Kothai
    Karatt-Vellatt, Aneesh
    Sahbudin, Ilfita
    Culbert, Eric
    Hextall, Patrick
    Clanchy, Felix I. L.
    Williams, Richard
    Marsden, Brian D.
    Raza, Karim
    Filer, Andrew
    Buckley, Christopher D.
    McCafferty, John
    Midwood, Kim S.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (04) : E43 - E43
  • [30] ASSESSING THE EFFECT OF INCREASED BODY MASS ON RESPONSE TO DMARD TREATMENT IN RHEUMATOID ARTHRITIS: RESULTS FROM THE METEOR DATABASE
    Dey, Mrinalini
    Zhao, Sizheng S.
    Psarelli, Eftychia-Eirini
    Moots, Robert J.
    Landewe, Robert
    Goodson, Nicola J.
    RHEUMATOLOGY, 2020, 59 : 42 - 42